SpyGlass Pharma CFO granted 17,500 stock options

SpyGlass Pharma, Inc. granted its Chief Financial Officer, Jean-Frederic Viret, a stock option covering 17,500 shares of common stock at an exercise price of $16 per share on February 5, 2026.

Rhea-AI Filing Summary

SpyGlass Pharma, Inc. granted its Chief Financial Officer, Jean-Frederic Viret, a stock option covering 17,500 shares of common stock at an exercise price of $16 per share on February 5, 2026.

According to the vesting terms, 25% of the option vests on the one-year anniversary of the February 5, 2026 vesting commencement date, with the remaining shares vesting in equal monthly installments over the following three years, contingent on continued service. After this grant, Viret directly holds derivative securities representing 17,500 underlying shares.

Insider Trade Summary

Grant/Award: 17,500 shares

Grant/Award 1 txn

Insider Viret Jean-Frederic

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	17,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 17,500 contracts (Direct)

Footnotes (1)

1. F1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 5, 2026.

FAQ

What did SpyGlass Pharma (SGP) disclose in this Form 4 filing?

SpyGlass Pharma disclosed a stock option grant to its Chief Financial Officer, Jean-Frederic Viret. The option covers 17,500 shares of common stock at a $16 exercise price, awarded on February 5, 2026, as part of his equity compensation.

How many SpyGlass Pharma (SGP) shares are covered by the CFO’s new option?

The Chief Financial Officer received a stock option covering 17,500 shares of SpyGlass Pharma common stock. These shares are not issued immediately; they become exercisable over time as the option vests according to the company’s 2026 Equity Incentive Plan terms.

What is the exercise price of the SpyGlass Pharma (SGP) CFO’s stock option?

The exercise price of the CFO’s stock option is $16 per share. This means he can buy up to 17,500 shares at $16 once the option vests, regardless of the market price at future exercise dates.

How does the stock option granted to SpyGlass Pharma (SGP)’s CFO vest?

The option vests over four years, starting February 5, 2026. Twenty-five percent vests on the one-year anniversary of that date, with the remaining shares vesting in equal monthly installments over the next 36 months, conditioned on continued service.

What role does Jean-Frederic Viret hold at SpyGlass Pharma (SGP)?

Jean-Frederic Viret serves as Chief Financial Officer of SpyGlass Pharma. The Form 4 shows he received a stock option grant tied to this role, aligning part of his compensation with the company’s common stock performance over a multi-year vesting period.

Is the SpyGlass Pharma (SGP) CFO’s new option a purchase or an award?

The transaction is an award, not an open-market purchase. It is coded as a grant or other acquisition of a derivative security, providing a stock option to buy 17,500 shares at $16, subject to the specified vesting schedule and continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/09/2026 - 04:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Viret Jean-Frederic

(Last) (First) (Middle)

C/O SPYGLASS PHARMA, INC.

27061 ALISO CREEK RD., SUITE 100

(Street)

ALISO VIEJO CA 92656

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SpyGlass Pharma, Inc. [ SGP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$16	02/05/2026		A		17,500		(1)	02/05/2036	Common Stock	17,500	$0	17,500	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 5, 2026.

	/s/ Brian Aukshunas, as Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.